Medication info
Pradicap 75 mg (Pregabalin)

Pradicap 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Korea PMG Pharmaceutical Co., Ltd.
Appearance
Hard capsule with a brownish-red upper and a white lower, containing white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201109152 · Approved 2011.10.25 · Insurance code 697100220

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is eliminated primarily by the kidneys; therefore, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50 % within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because data on safety and efficacy are insufficient. Adolescent patients aged 12 ~17 years: Administration is not recommended because data on safety and efficacy are insufficient.

Ingredients

Manufacturer
Korea PMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It also serves as an adjunctive therapy for partial seizures in epilepsy patients, effective regardless of the presence of secondary generalized symptoms. Additionally, it helps relieve pain in fibromyalgia patients. By acting safely and effectively on various neurological disorders and pain symptoms, it improves the quality of life of patients.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is eliminated primarily by the kidneys; therefore, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50 % within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because data on safety and efficacy are insufficient. Adolescent patients aged 12 ~17 years: Administration is not recommended because data on safety and efficacy are insufficient.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if mood changes or depressive symptoms occur during treatment, notify healthcare professionals immediately. Do not take this medication if you have had hypersensitivity reactions to it or have certain genetic disorders like lactose intolerance. Diabetic patients should be cautious as weight gain may necessitate adjustments in blood sugar control medication doses. If symptoms of angioedema occur, such as swelling of the face or around the mouth, discontinue use immediately. Elderly patients should be particularly careful during initial treatment due to the increased risk of accidents from dizziness or drowsiness. Transient blurred vision or changes in vision may occur; these symptoms may improve upon discontinuation of the medication. Discontinuing the medication suddenly may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered off gradually in consultation with a healthcare provider. This medication has a risk of misuse, so patients with a history of drug abuse should be particularly cautious and monitored for misuse or dependency symptoms during treatment. Patients with impaired kidney function may require dose adjustments. Patients with heart disease should use this medication with caution, as it may worsen symptoms of heart failure. Taking this medication in combination with opioid analgesics may increase the central nervous system depressant effects, posing a risk for respiratory depression. Pregnant women should avoid this medication during the early stages of pregnancy due to an increased risk of congenital malformations in the fetus, and women of childbearing age should use effective contraception. Breastfeeding women should avoid nursing while taking this medication, as it may be excreted in breast milk and affect the infant. Dangerous activities such as driving or operating machinery should be avoided until drowsiness or dizziness resolves after taking this medication. This medication may rarely cause serious skin reactions, so if any unusual symptoms such as rash or swelling occur, stop taking it immediately and consult a healthcare professional. In the case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and immediate medical attention is required where blood dialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 196 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • restlessness
  • affective lability
  • emotional flattening
  • emotional elevation
  • difficulty in finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attack
  • impulsivity
  • apathy
  • ataxia
  • abnormal coordination
  • balance disorder
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • speech disorders
  • sensory disturbances
  • sensory loss
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reflex reduction
  • abnormal movements
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremors during activity
  • syncope
  • stupor
  • psychomotor retardation
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • double vision
  • indirect visual loss
  • visual disturbances
  • visual field deficits
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hyperesthesia
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral vasoconstriction
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • alanine aminotransferase increase
  • serum creatine phosphokinase increase
  • aspartate aminotransferase increase
  • blood sugar increase
  • decreased platelet count
  • decreased potassium level
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. A temperature range of 15 to 30 degrees Celsius is recommended to maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Hard capsule with a brownish-red upper and a white lower, containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.